{"count": 68, "results": [{"_id": "35008275", "pmid": 35008275, "pmcid": "PMC8749852", "title": "Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma", "journal": "Cancers (Basel)", "authors": ["Guarnaccia L", "Marfia G", "Masseroli MM", "Navone SE", "Balsamo M", "Caroli M", "Valtorta S", "Moresco RM", "Campanella R", "Garzia E", "Riboni L", "Locatelli M"], "date": "2021-12-27T00:00:00Z", "doi": "10.3390/cancers14010112", "meta_date_publication": "2021 Dec 27", "meta_volume": "14", "meta_issue": "1", "meta_pages": "", "score": 50278.332, "text_hl": "Frontiers in Anti-@DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@Cancer@@@ Drug Discovery: Challenges and Perspectives of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as Anti-Angiogenic Add-On Therapy in @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@Glioblastoma@@@", "citations": {"NLM": "Guarnaccia L, Marfia G, Masseroli MM, Navone SE, Balsamo M, Caroli M, Valtorta S, Moresco RM, Campanella R, Garzia E, Riboni L, Locatelli M. Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma Cancers (Basel). 2021 Dec 27;14(1):. PMID: 35008275", "BibTeX": "@article{35008275, title={Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma}, author={Guarnaccia L and Marfia G and Masseroli MM and Navone SE and Balsamo M and Caroli M and Valtorta S and Moresco RM and Campanella R and Garzia E and Riboni L and Locatelli M}, journal={Cancers (Basel)}, volume={14}, number={1}}"}}, {"_id": "37278858", "pmid": 37278858, "pmcid": "PMC10244311", "title": "Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)", "journal": "Discov Oncol", "authors": ["Yoon WS", "Chang JH", "Kim JH", "Kim YJ", "Jung TY", "Yoo H", "Kim SH", "Ko YC", "Nam DH", "Kim TM", "Kim SH", "Park SH", "Lee YS", "Yim HW", "Hong YK", "Yang SH"], "date": "2023-06-06T00:00:00Z", "doi": "10.1007/s12672-023-00678-3", "meta_date_publication": "2023 Jun 6", "meta_volume": "14", "meta_issue": "1", "meta_pages": "90", "score": 50275.605, "text_hl": "However, the therapeutic implication of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@GBM@@@ is controversial due to a lack of well-designed clinical trials. ", "citations": {"NLM": "Yoon WS, Chang JH, Kim JH, Kim YJ, Jung TY, Yoo H, Kim SH, Ko YC, Nam DH, Kim TM, Kim SH, Park SH, Lee YS, Yim HW, Hong YK, Yang SH. Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study) Discov Oncol. 2023 Jun 6;14(1):90. PMID: 37278858", "BibTeX": "@article{37278858, title={Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)}, author={Yoon WS and Chang JH and Kim JH and Kim YJ and Jung TY and Yoo H and Kim SH and Ko YC and Nam DH and Kim TM and Kim SH and Park SH and Lee YS and Yim HW and Hong YK and Yang SH}, journal={Discov Oncol}, volume={14}, number={1}, pages={90}}"}}, {"_id": "32887267", "pmid": 32887267, "pmcid": "PMC7563149", "title": "An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin", "journal": "Biology (Basel)", "authors": ["Calvo Tardón M", "Marinari E", "Migliorini D", "Bes V", "Tankov S", "Charrier E", "McKee TA", "Dutoit V", "Dietrich PY", "Cosset E", "Walker PR"], "date": "2020-09-02T00:00:00Z", "doi": "10.3390/biology9090264", "meta_date_publication": "2020 Sep 2", "meta_volume": "9", "meta_issue": "9", "meta_pages": "", "score": 50273.723, "text_hl": "An Experimentally Defined @DISEASE_Hypoxia @DISEASE_MESH:D000860 @@@Hypoxia@@@ Gene Signature in @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@Glioblastoma@@@ and Its Modulation by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@", "citations": {"NLM": "Calvo Tardón M, Marinari E, Migliorini D, Bes V, Tankov S, Charrier E, McKee TA, Dutoit V, Dietrich PY, Cosset E, Walker PR. An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin Biology (Basel). 2020 Sep 2;9(9):. PMID: 32887267", "BibTeX": "@article{32887267, title={An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin}, author={Calvo Tardón M and Marinari E and Migliorini D and Bes V and Tankov S and Charrier E and McKee TA and Dutoit V and Dietrich PY and Cosset E and Walker PR}, journal={Biology (Basel)}, volume={9}, number={9}}"}}, {"_id": "35796457", "pmid": 35796457, "title": "The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme.", "journal": "Curr Med Chem", "authors": ["Sanati M", "Aminyavari S", "Mollazadeh H", "Motamed-Sanaye A", "Bibak B", "Mohtashami E", "Teng Y", "Afshari AR", "Sahebkar A"], "date": "2023-01-01T00:00:00Z", "doi": "10.2174/0929867329666220707103525", "meta_date_publication": "2023", "meta_volume": "30", "meta_issue": "7", "meta_pages": "857-877", "score": 50272.977, "text_hl": "The Potential Therapeutic Impact of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@Glioblastoma Multiforme@@@.", "citations": {"NLM": "Sanati M, Aminyavari S, Mollazadeh H, Motamed-Sanaye A, Bibak B, Mohtashami E, Teng Y, Afshari AR, Sahebkar A. The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme. Curr Med Chem. 2023;30(7):857-877. PMID: 35796457", "BibTeX": "@article{35796457, title={The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme.}, author={Sanati M and Aminyavari S and Mollazadeh H and Motamed-Sanaye A and Bibak B and Mohtashami E and Teng Y and Afshari AR and Sahebkar A}, journal={Curr Med Chem}, volume={30}, number={7}, pages={857-877}}"}}, {"_id": "35897747", "pmid": 35897747, "pmcid": "PMC9330793", "title": "Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin", "journal": "Int J Mol Sci", "authors": ["Feng SW", "Chang PC", "Chen HY", "Hueng DY", "Li YF", "Huang SM"], "date": "2022-07-25T00:00:00Z", "doi": "10.3390/ijms23158171", "meta_date_publication": "2022 Jul 25", "meta_volume": "23", "meta_issue": "15", "meta_pages": "", "score": 50269.066, "text_hl": "Exploring the Mechanism of Adjuvant Treatment of @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@Glioblastoma@@@ Using @CHEMICAL_Temozolomide @CHEMICAL_MESH:D000077204 @@@Temozolomide@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@", "citations": {"NLM": "Feng SW, Chang PC, Chen HY, Hueng DY, Li YF, Huang SM. Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin Int J Mol Sci. 2022 Jul 25;23(15):. PMID: 35897747", "BibTeX": "@article{35897747, title={Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin}, author={Feng SW and Chang PC and Chen HY and Hueng DY and Li YF and Huang SM}, journal={Int J Mol Sci}, volume={23}, number={15}}"}}, {"_id": "36077758", "pmid": 36077758, "pmcid": "PMC9454846", "title": "Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies", "journal": "Cancers (Basel)", "authors": ["Ohno M", "Kitanaka C", "Miyakita Y", "Tanaka S", "Sonoda Y", "Mishima K", "Ishikawa E", "Takahashi M", "Yanagisawa S", "Ohashi K", "Nagane M", "Narita Y"], "date": "2022-08-30T00:00:00Z", "doi": "10.3390/cancers14174222", "meta_date_publication": "2022 Aug 30", "meta_volume": "14", "meta_issue": "17", "meta_pages": "", "score": 50267.332, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ with @CHEMICAL_Temozolomide @CHEMICAL_MESH:D000077204 @@@Temozolomide@@@ for Newly Diagnosed @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@Glioblastoma@@@: Results of Phase I Study and a Brief Review of Relevant Studies", "citations": {"NLM": "Ohno M, Kitanaka C, Miyakita Y, Tanaka S, Sonoda Y, Mishima K, Ishikawa E, Takahashi M, Yanagisawa S, Ohashi K, Nagane M, Narita Y. Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies Cancers (Basel). 2022 Aug 30;14(17):. PMID: 36077758", "BibTeX": "@article{36077758, title={Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies}, author={Ohno M and Kitanaka C and Miyakita Y and Tanaka S and Sonoda Y and Mishima K and Ishikawa E and Takahashi M and Yanagisawa S and Ohashi K and Nagane M and Narita Y}, journal={Cancers (Basel)}, volume={14}, number={17}}"}}, {"_id": "33212778", "pmid": 33212778, "pmcid": "PMC7698156", "title": "Clinical Risk and Overall Survival in Patients with Diabetes Mellitus, Hyperglycemia and Glioblastoma Multiforme. A Review of the Current Literature", "journal": "Int J Environ Res Public Health", "authors": ["Montemurro N", "Perrini P", "Rapone B"], "date": "2020-11-17T00:00:00Z", "doi": "10.3390/ijerph17228501", "meta_date_publication": "2020 Nov 17", "meta_volume": "17", "meta_issue": "22", "meta_pages": "", "score": 50266.633, "text_hl": "...4.4. The Impact of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and Other Oral Antidiabetic Drugs on @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@GBM@@@ Patients", "citations": {"NLM": "Montemurro N, Perrini P, Rapone B. Clinical Risk and Overall Survival in Patients with Diabetes Mellitus, Hyperglycemia and Glioblastoma Multiforme. A Review of the Current Literature Int J Environ Res Public Health. 2020 Nov 17;17(22):. PMID: 33212778", "BibTeX": "@article{33212778, title={Clinical Risk and Overall Survival in Patients with Diabetes Mellitus, Hyperglycemia and Glioblastoma Multiforme. A Review of the Current Literature}, author={Montemurro N and Perrini P and Rapone B}, journal={Int J Environ Res Public Health}, volume={17}, number={22}}"}}, {"_id": "35135603", "pmid": 35135603, "pmcid": "PMC8822754", "title": "Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives", "journal": "J Exp Clin Cancer Res", "authors": ["Barbieri F", "Bosio AG", "Pattarozzi A", "Tonelli M", "Bajetto A", "Verduci I", "Cianci F", "Cannavale G", "Palloni LMG", "Francesconi V", "Thellung S", "Fiaschi P", "Mazzetti S", "Schenone S", "Balboni B", "Girotto S", "Malatesta P", "Daga A", "Zona G", "Mazzanti M", "Florio T"], "date": "2022-02-08T00:00:00Z", "doi": "10.1186/s13046-021-02213-0", "meta_date_publication": "2022 Feb 8", "meta_volume": "41", "meta_issue": "1", "meta_pages": "53", "score": 50265.977, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ exerts antitumor effects in @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@glioblastoma@@@ stem cells (GSCs) inhibiting @GENE_CLIC1 @GENE_1192 @@@CLIC1@@@ activity, but its low potency hampers its translation in clinical settings.", "citations": {"NLM": "Barbieri F, Bosio AG, Pattarozzi A, Tonelli M, Bajetto A, Verduci I, Cianci F, Cannavale G, Palloni LMG, Francesconi V, Thellung S, Fiaschi P, Mazzetti S, Schenone S, Balboni B, Girotto S, Malatesta P, Daga A, Zona G, Mazzanti M, Florio T. Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives J Exp Clin Cancer Res. 2022 Feb 8;41(1):53. PMID: 35135603", "BibTeX": "@article{35135603, title={Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives}, author={Barbieri F and Bosio AG and Pattarozzi A and Tonelli M and Bajetto A and Verduci I and Cianci F and Cannavale G and Palloni LMG and Francesconi V and Thellung S and Fiaschi P and Mazzetti S and Schenone S and Balboni B and Girotto S and Malatesta P and Daga A and Zona G and Mazzanti M and Florio T}, journal={J Exp Clin Cancer Res}, volume={41}, number={1}, pages={53}}"}}, {"_id": "36765551", "pmid": 36765551, "pmcid": "PMC9913744", "title": "GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status", "journal": "Cancers (Basel)", "authors": ["Moretti IF", "Lerario AM", "Sola PR", "Macedo-da-Silva J", "Baptista MDS", "Palmisano G", "Oba-Shinjo SM", "Marie SKN"], "date": "2023-01-18T00:00:00Z", "doi": "10.3390/cancers15030587", "meta_date_publication": "2023 Jan 18", "meta_volume": "15", "meta_issue": "3", "meta_pages": "", "score": 50265.914, "text_hl": "@<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@GBM@@@ Cells Exhibit Susceptibility to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Treatment According to @GENE_TLR4 @GENE_7099 @@@TLR4@@@ Pathway Activation and Metabolic and Antioxidant Status", "citations": {"NLM": "Moretti IF, Lerario AM, Sola PR, Macedo-da-Silva J, Baptista MDS, Palmisano G, Oba-Shinjo SM, Marie SKN. GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status Cancers (Basel). 2023 Jan 18;15(3):. PMID: 36765551", "BibTeX": "@article{36765551, title={GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status}, author={Moretti IF and Lerario AM and Sola PR and Macedo-da-Silva J and Baptista MDS and Palmisano G and Oba-Shinjo SM and Marie SKN}, journal={Cancers (Basel)}, volume={15}, number={3}}"}}, {"_id": "33372258", "pmid": 33372258, "title": "Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM).", "journal": "Turk Neurosurg", "authors": ["Albayrak G", "Konac E", "Dere UA", "Emmez H"], "date": "2021-01-01T00:00:00Z", "doi": "10.5137/1019-5149.JTN.29176-20.3", "meta_date_publication": "2021", "meta_volume": "31", "meta_issue": "2", "meta_pages": "233-237", "score": 50264.684, "text_hl": "Targeting @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@Cancer@@@ Cell Metabolism with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@, @CHEMICAL_Dichloroacetic_Acid @CHEMICAL_MESH:D003999 @@@Dichloroacetate@@@ and @CHEMICAL_Memantine @CHEMICAL_MESH:D008559 @@@Memantine@@@ in @<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@Glioblastoma@@@ (@<m>DISEASE_Glioblastoma</m> @DISEASE_MESH:D005909 @@@GBM@@@).", "citations": {"NLM": "Albayrak G, Konac E, Dere UA, Emmez H. Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM). Turk Neurosurg. 2021;31(2):233-237. PMID: 33372258", "BibTeX": "@article{33372258, title={Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM).}, author={Albayrak G and Konac E and Dere UA and Emmez H}, journal={Turk Neurosurg}, volume={31}, number={2}, pages={233-237}}"}}]}